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Abstract
Fibroblasts in monolayer culture secrete gelatinase A (MMP2; 72 kDa type IV collagenase) only in its proenzyme form.
Unlike other secreted matrix metalloproteinases, progelatinase A is refractory to activation by serine proteinases. Disparate
agents, including monensin, cytochalasin D, and concanavalin A, have been found to mediate the activation of gelatinase A
zymogen secreted by fibroblast monolayers. Our finding that monensin-mediated activation can be reversed by the protein
tyrosine kinase inhibitor genistein (Li et al., Experimental Cell Research 232 (1997) 332) prompted us to investigate the effect
of the specific inhibitor of protein tyrosine phosphatases, sodium orthovanadate, on progelatinase A activation. Treatment
of fibroblast monolayers with orthovanadate also results in the secretion of activated gelatinase A. This activation is dose-
and time-dependent, requires protein synthesis, and is associated with cell membranes. Vanadate-mediated activation does
not occur in the presence of herbimycin A, a protein tyrosine kinase inhibitor. As with progelatinase activation mediated by
monensin, concanavalin A, and cytochalasin D, orthovanadate treatment results in increased synthesis of the membrane
proteinase MT1-MMP, that can catalyze the activation of progelatinase A. Protein tyrosine kinase inhibitors are able to
prevent the increase of MT1-MMP mRNA, as shown by Northern blot and RT-PCR. In addition, orthovanadate potentiates
the effects of monensin and concanavalin A. While treatment with monensin or concanavalin A result only in an increase of
the putative activator MT1-MMP, orthovanadate also reduces the production of the specific inhibitor TIMP-2. These
experiments implicate protein tyrosine phosphorylation in the signal transduction pathways which lead to the activation of
progelatinase A. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
The matrix metalloproteinase gelatinase A
(MMP2; 72 kDa type IV collagenase) is thought to
play a major role in extracellular matrix degradation
during both normal and pathological processes, es-
pecially in tumor invasion and metastasis [1^3]. Like
all matrix metalloproteinases (MMPs), gelatinase A
is synthesized as an inactive zymogen and converts to
its active form by removal of the amino-terminal
pro-peptide. Unlike all other secreted MMPs, gelat-
inase A is refractory to activation by limited proteol-
ysis catalyzed by serine proteinases and other MMPs
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[4,5]. Although gelatinase A is found in a wide vari-
ety of human cell types and is implicated in a number
of disease processes, the physiological mechanisms
leading to its activation remain unclear.
Activation of gelatinase A at the cell plasma mem-
brane has been suggested by several studies [3,6].
This hypothesis is strengthened by the discovery of
a membrane-type matrix metalloproteinase (MT1-
MMP) that is able to activate gelatinase A [6].
Agents with di¡erent physical and chemical charac-
teristics, such as the lectin concanavalin A [7], the
sodium ionophore monensin [8], and the cytoskele-
tal-disrupting agent cytochalasin D [9,10] have been
found to stimulate activation of progelatinase A in
monolayer cultures of normal ¢broblasts. In addi-
tion, treatment of ¢brosarcoma cells and endothelial
cells with the tumor promoter phorbol myristic ace-
tate [11,12] results in progelatinase A activation. In
all these cases, MT1-MMP is upregulated [8,10,12^
14]. The exception is activation of gelatinase A by
¢broblasts cultured in a type I collagen lattice. In this
case, activation occurs intracellularly and is associ-
ated with Golgi-enriched intracellular membranes
[15,16]. MT1-MMP is not increased in collagen lat-
tice culture, but may well be the activating agent in
the Golgi, where MT1-MMP itself appears to be
converted from its zymogen form [15,16]. Production
of gelatinase A protein is increased in this system, as
it is with concanavalin A treatment of ¢broblast
monolayers [7].
We have previously shown [8] that monensin in-
duces a membrane associated activation of gelatinase
A in normal human skin ¢broblasts grown in mono-
layer culture. The monensin e¡ect on gelatinase A
activation is accompanied by an increase in MT1-
MMP production and is inhibited by the protein
kinase inhibitor genistein [8]. These results suggest
a role for protein tyrosine phosphorylation (PTP)
in the signal transduction pathways leading to acti-
vation of gelatinase A. Because tumor severity and
metastatic potential have been shown in many cases
to be correlated with the extent of gelatinase A acti-
vation [17,18], it is of great interest to further inves-
tigate the role of PTP in this process.
In this paper, we report that sodium orthovana-
date (vanadate), an inhibitor of tyrosine phospha-
tases [19], can itself induce a membrane-associated
activation of gelatinase A in monolayer cultures of
skin ¢broblasts. Vanadate also potentiates the e¡ects
of other activating agents, such as monensin or con-
canavalin A. Gelatinase A activation by vanadate, as
well as monensin and concanavalin A, can be re-
versed by certain protein tyrosine kinase inhibitors,
such as herbimycin A. These results support the hy-
pothesis that protein phosphorylation is involved in
the pathway leading to the activation of progelati-
nase A by MT1-MMP.
2. Materials and methods
2.1. Materials
Sodium orthovanadate (vanadate), cycloheximide
(CHX), genistein, gelatin, bovine albumin and con-
canavalin A were purchased from Sigma (St. Louis,
MO). Lavendustin A was purchased from LC Labo-
ratories (Woburn, MA). Herbimycin A and monen-
sin were obtained from Calbiochem (La Jolla, CA).
Alkaline phosphatase-conjugated anti-chicken, anti-
mouse and anti-rabbit antibodies were purchased
from Sigma. TIMP-2 antibody was purchased from
Triple Point Biologics (Forest Grove, OR). Mono-
clonal antibody to MT1-MMP was a kind gift
from Dr. H. Seiki (Kanazawa University, Japan).
TIMP-2 was puri¢ed from culture medium produced
by a recombinant cell line (generous gift from Dr.
Gregory Goldberg, Washington University School
of Medicine) by established protocols [11].
2.2. Cell culture
Human ¢broblast cell strains were established
from normal adult skin by outgrowth from explants
as previously described [20]. Cultures were main-
tained with DME/F12 medium containing a mixture
of 5% newborn calf serum (Biowhittaker) and 3%
bovine embryonic £uid (Sigma). All cultures of nor-
mal ¢broblast cells used in this study were between
passages 3 and 11. In order to exclude interference
resulting from latent and active gelatinase A existing
in serum and embryonic £uid, experiments were
performed in serum free DME/F12 medium contain-
ing insulin-transferrin-selenium (ITS) culture supple-
ment (Collaborative Biomedical Products). ITS me-
dium has been previously shown to be an adequate
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serum substitute for several days of serum-free cul-
ture [21].
Cell viability was measured with the colorimetric
cytotoxicity method of Alley et al. [22].
2.3. Fibroblast populated collagen lattices
Collagen lattices were prepared using sterile type I
collagen from rat tail tendons as previously described
[15]. Concentrations of collagen in the lattice varied
from 0.5 to 1 mg/ml. Lattice mixtures were made in
pH-adjusted DME/F12 so that the culture conditions
were identical to the control monolayer plates. Col-
lagen-containing mixtures were kept at 4‡C until the
addition of cells. After mixing, aliquots of 1^2 ml
were pipetted into 35 mm bacteriological dishes
that had been precoated with bovine serum albumin
to prevent ¢broblast adhesion. Gelation began imme-
diately and was completed in less than 2 min at 37‡C,
trapping the cells within the lattice. Cultures were
incubated at 37‡C in an atmosphere of 95% air, 5%
CO2. After 1 h, lattices were detached from the sides
of the dish by gentle tapping.
2.4. Zymogram analysis of proenzyme activation
Latent and active gelatinases were detected by zy-
mogram analysis using SDS-polyacrylamide gels co-
polymerized with 2.5% gelatin as previously de-
scribed [23]. These enzymes become dissociated
from TIMP’s by the presence of SDS during electro-
phoresis. Removal of SDS following electrophoresis
allows the proenzymes to renature in an active or
partially active conformation. This permits their de-
tection and the detection of lower molecular weight
activated forms [24,25]. In brief, conditioned medium
or whole cell lysate was mixed with sample bu¡er
and electrophoresed directly without boiling or re-
duction. Following electrophoresis, SDS was ex-
tracted from the polyacrylamide gel with Triton
X-100, and the gel was incubated in 0.05 M Tris,
pH 7.5, containing 5 mM CaCl2, and 5 WM ZnCl2
at 37‡C overnight. Gels were stained with Coomassie
blue and destained. Both proenzyme and active ge-
latinase were detected as clear bands against the blue
background of the stained gelatin.
2.5. Preparation of whole cell lysate and subcellular
fractionation for cellular activation of
biosynthetically labeled gelatinase A
Normal ¢broblasts were grown to con£uence and
treated with 100 WM vanadate in the presence or
absence of 10 Wg/ml cycloheximide (CHX) under se-
rum-free conditions for 48 h. Following treatment,
conditioned medium was removed and retained,
and the cells were fractionated into a crude cell mem-
brane fraction and a cytosolic fraction as described
by Brown et al. [26]. The cells were incubated with
lysis bu¡er containing 50 mM Tris-HCl pH 7.5,
0.2 M NaCl, 0.2% (v/v) Brij-35 and protease inhib-
itors including 1 Wg/ml leupeptin (Sigma, L-2884),
10 Wg/ml pepstatin A (Sigma, P-4265), 10 Wg/ml
aprotinin (Sigma, A-1153) and 1 mM pefabloc
(Boehringer Mannheim) for 30 min at 4‡C. After
vigorous vortexing, this whole cell lysate was used
for zymogram analysis.
For preparation of crude cell membranes and cy-
tosolic fractions, the initial cell lysate was centrifuged
at 2000Ug for 30 min at 4‡C. The supernatant was
collected as the cytosolic fraction, and the cell resi-
due resuspended in lysis bu¡er as a crude membrane
fraction. Protein content was determined by Brad-
ford’s method [27] with bovine serum albumin as
standard.
In order to determine which fraction is involved in
the activation of progelatinase A, 20 Wg of cytosol or
crude membrane protein, and 20 Wl of concentrated
conditioned medium (15-fold concentration) were in-
cubated with 5 or 10 Wl of 35S-labeled gelatinase A at
37‡C for 48 h. The samples were then separated on
12% SDS-polyacrylamide gels, and the gels dried and
processed for autoradiography. 35S-Labeled gelati-
nase A used in this study was prepared and puri¢ed
as previously described [23].
2.6. Western immunoblotting analysis
Conditioned medium and cell extracts were elec-
trophoresed on 10 or 12% SDS-polyacrylamide gels,
and electrophoretically transferred to a polyvinyl-
idene di£uoride membrane (Millipore) following the
product directions. After blockage of non-speci¢c
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binding sites with non-fat milk, blots were incubated
1 h at room temperature with primary antibody.
After extensive washing, blots were incubated with
alkaline phosphatase-conjugated second antibodies,
and developed with BCIP-NBT (Kirkegaard-Perry).
The primary antibody for immunostaining of gelati-
nase A was raised in chickens and a⁄nity puri¢ed
using a column of gelatinase A coupled to A⁄-gel
10. A polyclonal rabbit antibody to a unique peptide
was used for immunodetection of TIMP-2, and a
monoclonal anti-peptide antibody to MT1-MMP
was used in Western blotting analysis of that en-
zyme.
2.7. Detection of tyrosine-phosphorylated proteins by
Western immunoblotting
Normal ¢broblasts were treated with vanadate in
serum-free DME/F12 medium. At indicated time
points, the medium was discarded and the cell layer
rapidly rinsed with HBSS. The cell layer was then
lysed with 0.5 ml lysis bu¡er containing 1% SDS,
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 100 mM
vanadate, 100 mM NaF, 1 Wg/ml leupeptin, 10 Wg/ml
pepstatin A, 10 Wg/ml aprotinin and 1 mM pefabloc.
The lysate was brie£y sonicated, centrifuged at
14 000Ug for 25 min to remove insoluble material,
and assayed for protein concentration using the BCA
protein reagent (Pierce). 20^30 Wg of sample protein
was mixed with sample bu¡er containing 10 mM
DTT, boiled 5 min, and subjected to SDS-PAGE
and electrophoretic transfer to a polyvinylidene di-
£uoride membrane (PVDF membrane). After non-
speci¢c binding sites were saturated with blocking
bu¡er (1% bovine albumin in 20 mM Tris, pH 7.5,
150 mM NaCl, 0.1% Tween), the membranes were
incubated 1 h at room temperature with horseradish
peroxidase conjugated anti-phosphotyrosine (RC20,
Transduction Laboratories, Lexington, KY). After
extensive washing, tyrosine-phosphorylated proteins
were detected with ECL reagents (Amersham).
2.8. Quantitation of MT1-MMP mRNA
2.8.1. Total cellular RNA preparation and Northern
blot analysis
Cells were cultured in the presence of vanadate
(100 WM) for 24 h. Total cellular RNA was extracted
with the Trizol Kit (Gibco-BRL). 20 Wg of total
RNA was denatured at 95‡C for 3 min and separated
on formaldehyde^1% agarose gels, transferred to Ny-
lon membranes by standard capillary blotting, and
¢xed at 80‡C. Northern blot analysis was performed
with cDNA probes labeled with [K-32P]dCTP (Amer-
sham, 3000 Ci/mmol) using Klenow enzyme. The
MT1-MMP cDNA probe was a gift from Dr. Greg-
ory Goldberg (Washington University). Quantitation
was performed by direct densitometric measurement
of the bands seen on X-ray ¢lms using the NIH
Image (version 1.61).
2.8.2. RT-PCR analysis
RT-PCR was performed according to the protocol
in the Perkin-Elmer GenAmp RNA PCR kit with the
following modi¢cations: the ¢rst strand cDNA was
synthesized following kit instructions, but using 2 or
3 Wg of total RNA and 200 units of M-MLV (Gibco)
in a total volume of 20 Wl. Reverse transcription
proceeded for 1 h at 42‡C, followed by a 5 min in-
cubation at 99‡C to inactivate M-MLV. After cool-
ing to 4‡C for 5 min the samples were kept on ice for
PCR.
The sense and anti-sense primers used for MT1-
MMP were, respectively, 5P-CTCTCTTCTGGAT-
GCCCAAT-3P and 5P-CCTCAATGATGATCAC-
CTCC-3P, giving a PCR product of 350 bp [28].
GAPDH was used as an internal standard [29,30],
with the sense primer 5P-ACTCTGGTAAAGTG-
GATATTG-3P and the antisense primer 5P-TCCCG-
TTCAGCTCAGGGATGA-3P, giving a PCR prod-
uct of 567 base pairs. Both MT1-MMP and GAPDH
genes were ampli¢ed in one reaction tube. Ampli¢-
cation was carried out in a 20 Wl volume using the
Perkin^Elmer GeneAmp PCR system 2400 with a
program consisting of 95‡C for 2 min to denature
followed by 45 cycles of 95‡C for 15 s and 60‡C
for 30 s (anneal-elongation), and a ¢nal 10 min ex-
tension at 72‡C. Following ampli¢cation, samples
were electrophoresed on 1% agarose gels containing
ethidium bromide in 1UTAE bu¡er. Gels were pho-
tographed under UV light using the Kodak Digital
Science 1D Image Analysis system and bands quan-
titated by direct densitometric measurement using
NIH Image (version 1.61).
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3. Results
3.1. Orthovanadate (vanadate) induces 72 kDa
gelatinase A activation in human dermal
¢broblasts
Normal human dermal ¢broblasts in monolayer
culture secrete only the proenzyme of gelatinase A.
However, zymograms of conditioned medium from
vanadate-treated monolayer cultures showed an in-
duction of active gelatinase A in a dose-dependent
manner (Fig. 1A). This induction was con¢rmed by
immunoblotting using polyclonal anti-gelatinase A
antibody (Fig. 1A). The extent of gelatinase A acti-
vation induced by vanadate is comparable to that
produced by such agents as concanavalin A or cul-
turing ¢broblasts in a type I collagen lattice (Fig.
1B).
3.2. Vanadate-induced gelatinase A activation is
associated with cell membranes and requires
protein synthesis
As shown in Fig. 2, incubation of exogenous 35S-
labeled progelatinase A with a total cell membrane
fraction (including ER, Golgi and plasma mem-
branes) prepared from vanadate-treated ¢broblasts
showed that only membranes prepared from vana-
date-treated cultures (lane C, Fig. 2) result in a
marked activation of exogenous proenzyme. Mem-
branes prepared from control monolayer cultures
(lane B, Fig. 2) did not show activation. Neither
the cytosolic fraction nor concentrated conditioned
medium was able to activate labeled gelatinase A
(data not shown). Membranes isolated from cultures
incubated with 100 WM vanadate and 10 Wg/ml cyclo-
heximide, a protein translation inhibitor (lane D,
Fig. 2), did not activate exogenous proenzyme, sug-
gesting that protein synthesis is involved in vanadate-
mediated activation of progelatinase A.
Fig. 1. Orthovanadate induces activation of progelatinase A in
monolayer cultures of normal human dermal ¢broblasts. (A)
Dose response showing activation of progelatinase A with in-
creasing concentrations of orthovanadate. Con£uent ¢broblasts
were incubated with increasing doses of vanadate in ITS-serum
free medium for 48 h. Medium was collected and directly sub-
jected to zymography as described in Section 2. For immuno-
blot analysis, aliquots containing equal amounts of protein
from concentrated medium were electrophoresed and trans-
ferred. Development of the immunoblot was performed as de-
scribed in Section 2. Medium from a gelatinase A overexpres-
sion clone P211A [55] was incubated with 1 mM APMA at
room temperature for 2 h and used as a positive control of ac-
tive gelatinase A. (B) Comparison of gelatinase A activation in
normal human ¢broblasts mediated by di¡erent agents. Equal
amounts of cells were incubated with the agents indicated for
48 h. Medium was directly subjected to zymography. (A) Me-
dium from ITS-serum-free (ITS-SF) control cultures incubated
with 1 mM APMA for 2 h at room temperature. (B) Medium
from ITS-serum-free monolayer culture. (C) Medium from ¢-
broblast monolayer culture in ITS-SF medium containing
100 WM vanadate. (D) Medium from type I collagen lattice cul-
ture. (E) Medium from ¢broblast monolayer cultured in ITS-SF
medium containing 20 Wg/ml concanavalin A.
Fig. 2. Cell membrane associated activation of gelatinase A by
vanadate and the e¡ect of cycloheximide on activation. Fibro-
blasts were cultured for 48 h in ITS-SF medium þ 100 WM va-
nadate and/or 10 Wg/ml cycloheximide. Cells were harvested,
separated into crude cytoplasmic and cell membrane fractions
as described in Section 2. Twenty Wg of membrane protein was
then incubated with 35S metabolically labeled pure gelatinase A
proenzyme for 48 h at 37‡C before electrophoresis and autora-
diography. (A) 35S-Progelatinase A alone. (B) 35S-Progelatinase
A+membranes from monolayer control ¢broblasts. (C) 35S-Pro-
gelatinase A+membranes from monolayer ¢broblasts incubated
with 100 WM vanadate. (D) 35S-Progelatinase A+membranes
from monolayer ¢broblasts incubated with both 100 WM vana-
date and 10 Wg/ml cycloheximide. (E) 35S-Progelatinase
A+membranes from monolayer ¢broblasts incubated with 10 Wg/
ml cycloheximide.
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3.3. Vanadate acts synergistically with other agents
that activate gelatinase A
We have previously shown that the protein tyro-
sine kinase inhibitor genistein prevents monensin-in-
duced activation of gelatinase A in ¢broblast mono-
layers [8]. Since vanadate inhibits protein tyrosine
phosphatases, and thus potentiates the action of ty-
rosine kinases, it was of interest to see if it would
potentiate the action of agents mediating the activa-
tion of gelatinase A. For this purpose, very low doses
(1/10 optimal) of monensin or concanavalin A were
added to ¢broblast cultures together with a low con-
centration of vanadate. After a 48 h incubation, me-
dium was collected and analyzed by gelatin zymog-
raphy. As shown in Fig. 3A, neither 30 WM vanadate
nor 1 WM monensin alone is su⁄cient to mediate
activation of gelatinase A. However, when mono-
layer cultures were incubated with both 30 WM va-
nadate and 1 WM monensin, considerable activation
was observed. Similar results were obtained with 30
WM vanadate, and a concentration of concanavalin
A which is 1/10 that needed for optimal activation (2
Wg/ml) (Fig. 3B). Quantitation of both pro- and ac-
tive bands using NIH Image 1.61 software clearly
exhibit a marked increase of active gelatinase A in
cells treated with both agents (not shown). These
results show that vanadate, an inhibitor of protein
tyrosine phosphatase, not only induces gelatinase A
activation itself, but also potentiates the e¡ect of
other agents, again indicating the involvement of
protein tyrosine phosphorylation in the pathways
leading to activation of gelatinase A.
3.4. The protein tyrosine kinase inhibitor herbimycin
A decreases activation of gelatinase A
To further address involvement of protein tyrosine
phosphorylation in the activation of gelatinase A by
¢broblasts in monolayer culture, the e¡ects of pro-
tein tyrosine kinase inhibitors were investigated. Of
the inhibitors tested (genistein, herbimycin A, and
lavendustin A), only herbimycin A was able to inhib-
it activation in both systems (Fig. 4). Genistein was
Fig. 3. Zymograms showing that vanadate acts synergistically
with other gelatinase A activating agents. (A) Monensin was
added to monolayer ¢broblast cultures for 48 h at an activating
concentration and at a concentration which did not give detect-
able activation by zymography. When vanadate at a suboptimal
dose was included with the low dosage of monensin, activation
of gelatinase A was detected. (B) An identical experiment to
(A), but using low concentrations of concanavalin A.
Fig. 4. Inhibition of protein tyrosine phosphorylation by herbi-
mycin A inhibits progelatinase A activation by vanadate and
monensin. Dermal ¢broblasts were cultured in ITS-serum free
medium containing either 100 WM orthovanadate (A) or 10 WM
monensin (B). The indicated concentrations of herbimycin A
were added at the beginning of the incubation. Medium was
collected after 30 h and subjected to gelatin zymography.
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able to reverse monensin-mediated activation of ge-
latinase A in monolayer culture, and lavendustin A
reversed the activation mediated by vanadate (not
shown). These results indicate that inhibition of pro-
tein tyrosine kinases can result in inhibition of gelat-
inase A activation.
3.5. Patterns of tyrosine phosphorylation in cellular
proteins were observed in ¢broblasts in response
to monensin and vanadate treatment
Western immunoblots showed an increase in tyro-
sine phosphorylation of speci¢c proteins in response
to both vanadate and monensin treatment (Fig. 5).
As expected, vanadate treatment resulted in accumu-
lation of phosphorylated proteins in a dose-depend-
ent and time-dependent fashion (Fig. 5A,B). Several
of these bands, at approximately 190 and 130 kDa,
appeared to be the same as bands phosphorylated in
response to monensin treatment (Fig. 5C).
3.6. E¡ect of orthovanadate on MT1-MMP
expression
Northern blots of total RNA from normal ¢bro-
blasts treated with 100 WM orthovanadate for 24 h
showed a nearly two-fold increase in mRNA for
MT1-MMP, a membrane-bound matrix metallopro-
teinase that can activate progelatinase A (Fig. 6A).
RT-PCR was used to compare the production of
MT1-MMP mRNA by ¢broblasts in response to or-
thovanadate, monensin, and concanavalin A with or
Fig. 5. Tyrosine phosphorylation of cell proteins from vanadate- and monensin-treated ¢broblasts. Fibroblast cultures were exposed
to monensin and vanadate as indicated. Tyrosine-phosphorylated proteins were detected by horseradish peroxidase conjugated anti-
phosphotyrosine antibody (RC20, Transduction Laboratories) as described in Section 2. (A) Time course of tyrosine phosphorylation
in cells exposed to 300 WM vanadate (V). The control was incubated in ITS-serum free medium for 20 min. (B) Dose response show-
ing phosphorylation in ¢broblasts exposed to ITS-serum-free medium containing increasing concentration of vanadate for 15 min. (C)
Time course of tyrosine phosphorylation in cells exposed to 10 WM monensin. The control was incubated in ITS-serum free medium
for 120 min.
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without herbimycin A. As shown in Fig. 6B, treat-
ment of monolayer cultures with vanadate (lane 9),
monensin (lanes 3 and 7), and concanavalin A (lane
5) resulted in increased production of MT1-MMP
mRNA. In all cases, when 5 WM herbimycin A was
added to the incubations with the above agents
(lanes 4, 6, 8 and 10), MT1-MMP mRNA remained
near baseline levels, indicating that inhibition of pro-
tein tyrosine phosphorylation inhibits the upregula-
tion of this enzyme by the agents investigated. Fig.
6B shows the results from two di¡erent experiments.
The decrease in monensin-mediated MT1-MMP
mRNA shown in lanes 7 and 8 con¢rms the results
shown in lanes 3 and 4.
3.7. Coordinated increase in MT1-MMP and decrease
in TIMP-2 is found in response to orthovanadate
treatment of ¢broblast monolayers
Immunoblot analysis of cell lysates showed that
upregulation of the message for MT1-MMP resulted
in increased synthesis of the protein. Quantitation of
the Western immunoblot using NIH Image 1.61
showed a ¢ve-fold increase in both pro- and active
MT1-MMP protein in monolayer cultures treated
with vanadate (Fig. 7A), further implicating speci¢c
protein synthesis in the response to the phosphatase
inhibitor. This increase in the putative gelatinase-ac-
tivating enzyme is accompanied by a concurrent de-
crease in tissue inhibitor of metalloproteinase-2
(TIMP-2) in culture medium, as shown in Fig. 7B.
A decrease in TIMP-2, which is often secreted in a
complex with progelatinase A could indicate an in-
creased amount of uncomplexed, and theoretically
readily activatable proenzyme to serve as a substrate
for MT1-MMP.
4. Discussion
Since inhibitors of matrix metalloproteinases have
been shown to have anti-invasive and anti-metastatic
e¡ects [31,32], and since overexpression of TIMPs,
the protein inhibitors of MMPs, also have anti-
Fig. 6. Increase in MT1-MMP mediated by orthovanadate, and reversal of MT1-MMP induction by inhibitors of tyrosine phosphoryl-
ation. (A) Northern blot analysis of total RNA from ¢broblast monolayer cultures. C, control; V, 100 WM vanadate (B) Con£uent
monolayer ¢broblasts were incubated with combinations of herbimycin A (Her A), monensin (Mon), orthovanadate (Van) and conca-
navalin A (Con A) for 24 h in ITS serum free medium. Total RNA was then isolated and subjected to RT-PCR as described in Sec-
tion 2. GAPDH, which was ampli¢ed with MT1-MMP in the same tube, was used as an internal standard.
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metastatic e¡ects [33,34], it can be concluded that
active gelatinase A is the important form of the
enzyme in disease processes. In many cases, direct
correlations have been made between tumor aggres-
sion and extent of gelatinase A activation [17,18,35^
37]. Elucidation of mechanisms leading to the pro-
duction of active gelatinase A is thus of major im-
portance.
Previously, we have shown that gelatinase A acti-
vation mediated by monensin can be prevented by
incubation with the protein tyrosine kinase inhibitor
genistein [8]. Here we show that orthovanadate,
which inhibits dephosphorylation catalyzed by pro-
tein tyrosine phosphatases, can induce a dose-de-
pendent, cell membrane-associated activation of ge-
latinase A. Furthermore, vanadate is able to
potentiate the e¡ects of other agents that mediate
activation of gelatinase A and apparently act via
pathways involving protein tyrosine phosphoryla-
tion. Inhibitors of protein tyrosine kinases prevent
vanadate-mediated and monensin-mediated activa-
tion of progelatinase A. Indeed, Western blotting
for protein tyrosine phosphate indicates that several
of the proteins phosphorylated in response to mon-
ensin also correspond to bands showing increased
phosphorylation when normal ¢broblasts are treated
with orthovanadate. The identity of these bands is
under investigation.
Incubation of ¢broblast monolayers with monen-
sin, vanadate, or concanavalin A results in an in-
crease of MT1-MMP, a membrane-bound metallo-
proteinase that can activate progelatinase A. The
results shown in this study indicate that protein ty-
rosine kinase signal transduction cascades are in-
volved in the up-regulation of this protein. Further
support comes from the PCR experiments in which
MT1-MMP mRNA levels were maintained at base-
line when 5 WM herbimycin was included in the pres-
ence of an activating concentration of monensin, va-
nadate, or concanavalin A. However, despite the
similarities between monensin- and vanadate-medi-
ated activation of progelatinase A, the signalling
pathways involved must di¡er, since only vanadate
treatment results in decreased production of the spe-
ci¢c protein inhibitor TIMP-2. This dual target may
explain the synergistic e¡ect of vanadate and other
activating agents. The potentiation of monensin and
concanavalin A activation of gelatinase A by vana-
date might be due to the availability for activation of
a greater percentage of total proenzyme not com-
plexed to TIMP-2. Earlier work showed that the
TIMP-2-progelatinase A complex is more di⁄cult
Fig. 7. Western blots display a coordinated increase of MT1-MMP and decrease of TIMP-2 in response to vanadate treatment. Con-
£uent monolayers of ¢broblasts were incubated with 100 WM vanadate in ITS-serum free medium for 48 h. Medium was collected
and the cell layer was lysed for immunoblotting of MT1-MMP using a monoclonal antibody. Equal amounts of cell protein were elec-
trophoresed prior to electrotransfer. Equal amounts of medium protein were electrophoresed and immunoblotted for TIMP-2 using a
peptide-antibody. (A) Immunoblot for MT1-MMP: Lane 1, Control cell lysate; lane 2, cell lysate from 100 WM vanadate cultures.
The two bands correspond to pro- and active enzyme. (B) Immunoblots for TIMP-2: Lane 1, puri¢ed TIMP-2; lanes 2 and 3, 25 Wg
medium protein from control cultures; lanes 4 and 5, 25 Wg medium protein from cultures incubated with 100 WM vanadate.
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to activate than uncomplexed proenzyme [18,38].
Subsequent experiments showed that TIMP-2 can
actually potentiate progelatinase A activation when
present in a very precise ratio to MT1-MMP, but
that a very slight increase in the TIMP-2:MT1-
MMP ratio will inhibit activation [11,39]. The experi-
ments described in this paper do not permit the
quantitation that would be required to accurately
interpret the role of reduced TIMP-2 production in
this system.
It should be pointed out that in the case of integ-
rin-mediated progelatinase A activation in the type I
collagen lattice, we have previously shown that MT1-
MMP and TIMP-2 levels are unchanged, while pro-
duction of gelatinase A itself is up-regulated [15,16].
Clearly, similar end results can be achieved by alter-
ing the relationships between the components of the
system; i.e. the proenzyme, the activator, and the
inhibitor.
The agents that mediate activation of progelati-
nase A are seemingly quite disparate in their proper-
ties. For example, monensin is a sodium ionophore,
while concanavalin A is a lectin. However, all of the
agents investigated to date, including the mechani-
cally relaxed collagen lattice [40^42], produce major
changes in the cytoskeletal organization. We have
found striking, but quite di¡erent morphologic
changes when normal ¢broblasts were exposed to
monensin, vanadate, and concanavalin A in mono-
layer cultures (data not shown). These changes are
correlated with marked changes in the actin cytoske-
leton, as shown by immuno£uorescent staining with
phalloidin. It is well documented that tyrosine phos-
phorylations play a crucial role in the regulation of
cytoskeletal functions [43^46]. Components of the
cytoskeleton play a role in passing signals from the
extracellular environment to the nucleus to regulate
gene expression [47^49]. For instance, binding of ex-
tracellular matrix molecules to their integrin recep-
tors elicits tyrosine phosphorylation of the cytoske-
letal molecules paxillin and tensin [50,51], initiating a
cascade of signals that alter expression of many
genes. Furthermore, Tomasek et al. [40] have shown
that the organization of the polymerized actin cytos-
keleton is an important factor in the regulation of
gelatinase A activation.
Matrix metalloproteinase inhibitors have been
shown to be e¡ective anti-tumor and anti-metastatic
agents in cell culture and animal models
[31,33,34,37,52]. Clinical trials in humans are in the
early stages, and have been somewhat promising
[31,53,54]. Because of the strong correlations often
observed between tumor aggressiveness and extent
of gelatinase activation, it is essential to dissect the
pathways leading to such activation. The experi-
ments described in this paper indicate that protein
tyrosine phosphorylations are involved in at least
some of these pathways.
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